Long-Term Oral Treatment with Non-Hypoglycemic Dose of Glibenclamide Reduces Diabetic Retinopathy Damage in the Goto-KakizakiRat Model

Diabetic retinopathy (DR) remains a major cause of vision loss, due to macular edema, retinal ischemia and death of retinal neurons. We previously demonstrated that acute administration of glibenclamide into the vitreous, or given orally at a non-hypoglycemic dose, protected the structure and the fu...

Description complète

Enregistré dans:
Détails bibliographiques
Publié dans:Pharmaceutics
Auteurs principaux: Berdugo, Marianne, Delaunay, Kimberley, Lebon, Cécile, Naud, Marie-Christine, Radet, Lolita, Zennaro, Léa, Picard, Emilie, Daruich, Alejandra, Beltrand, Jacques, Kermorvant-Duchemin, Elsa, Polak, Michel, Crisanti, Patricia, Behar-Cohen, Francine F.
Format: Artigo
Langue:Inglês
Publié: MDPI 2021
Sujets:
Article
Accès en ligne:https://ncbi.nlm.nih.gov/pmc/articles/PMC8308933/
https://ncbi.nlm.nih.gov/pubmed/34371786
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3390/pharmaceutics13071095
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires